Tullika Garg discusses treatment burden and a goal elicitation communication tool for older adults with non-muscle invasive bladder cancer. High-risk NMIBC can require up to 19 or ...
Sara Khor presents a study linking pre-diagnosis financial hardship to late-stage cancer diagnosis, drawing on SEER, TransUnion credit report, and insurance claims data from appro ...
Overview on the use of androgen deprivation therapy (ADT) added to salvage radiation therapy (SRT) for prostate cancer patients with biochemical recurrence after prostatectomy. Th ...
Alicia Morgans is joined by Arnoud Templeton to discuss the REDUSE trial. This non-inferiority study compares denosumab administered every four weeks versus twelve weeks in patients with metastatic ...
(UroToday.com) The 2023 ASCO annual meeting included a kidney cancer session, featuring a presentation by Dr. Brian Rini discussing the 5-year analysis of KEYNOTE-426, assessing pembrolizumab + ...
Neeraj Agarwal discusses TALAPRO-3, a 599-patient phase 3 trial randomizing HRR-mutated metastatic hormone-sensitive prostate cancer patients to ADT plus enzalutamide plus talazoparib versus ADT plus ...
Hunner lesions (HL) are distinctive ulcerative bladder lesions characterized by a central scar and surrounding erythema. Traditionally, HL has been used as a clinical diagnostic tool for a subset of ...
Randomized trials demonstrated improved survival in metastatic prostate cancer (mPCa) with the adoption of several systemic therapies. However, real-world data validating this effect and quantifying ...
Real-World Effectiveness and Treatment Persistence of Darolutamide, Apalutamide, and Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Study - Beyond the Abstract ...
Transdermal Application of H100 Gel to the Penile Shaft in Patients with Peyronie's Disease Infiltrates the Tunica Albuginea - Beyond the Abstract ...
The role of microRNAs-23b and 27b in migration, invasion and proliferation of T24 bladder cancer cells. July 6, 2026 Assessing Human Epidermal Growth Factor Receptor 2 in Urothelial Carcinoma: ...
First Use of the FloStent™ for Catheter-Dependent Urinary Retention Secondary to BPH: Additional Results from the RAPID I Study - Beyond the Abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results